ArticlePoultry science2026
Effect of intracerebroventricular (ICV) injection of antimicrobial peptide expressed in the body-2 (LEAP-2) and its interaction with cannabinoid and ghrelin systems on food intake in broiler chickens.
Article in Poultry science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Liver-expressed antimicrobial peptide 2 (LEAP-2), initially identified as an antimicrobial peptide which endocannabinoid and ghrelin action may occur via changes in Leap2 expression. This study aimed to determine effect of ICV injection of LEAP2and its interaction with cannabinoid and ghrelin systems on food intake in broiler chickens. In the present study 4 experiments were conducted, each containing 4 experimental groups. In experiment 1, chicken injected with group 1 ICV injection of saline, group 2 with LEAP2 (0.75 nmol), group 3 with LEAP2 (1.5 nmol) and group 4 with LEAP2 (3 nmol). In experiment 2, chicken received ICV injections as group 1: saline, group 2: (D-Lys-3)-GHRP-6 (0.5 nmol), group 3: LEAP2 (3 nmol) and group 4 with co injection of the (D-Lys-3)-GHRP-6 + LEAP2. In experiment 3 chiken received ICV inejctions as: group 1: saline, group 2: SR141716A (6.25 µg), group 3: LEAP2 (3 nmol) and group 4 with co injection of the SR141716A + LEAP2. In experiment 4 chiken received ICV inejctions as: group 1: saline, group 2: AM630 (1.25 µg), group 3: LEAP2 (3 nmol) and group 4 with co injection of the AM630 + LEAP2. Immediately following the infusions, the broilers were returned to their respective boxes, where they were provided with pre-weighed meal and fresh water ad libitum. The cumulative meal consumption was subsequently measured at intervals of 30, 60, and 120 min post-administration. According to the results, ICV injection of the LEAP2 (1.5 and 3 nmol) significantly decreased food intake (P<0.05). Co-injection of the (D-Lys-3)-GHRP-6 + LEAP2 significantly decreased LEAP2-induced hypophagia (P<0.05). Co-injection of the (D-Lys-3)-GHRP-6 + LEAP2 significantly increased hypophagic effect of the LEAP2 (P<0.05). Co-injection of the SR141716A + LEAP2 significantly amplified LEAP2-induced hypophagia compared to control group (P<0.05). Co-injection of the AM630 + LEAP2 significantly amplified LEAP2-induced hypophagia compared to control group (P<0.05). These results suggested that LEAP2-induced hypophagia mediates via ghrelin and CB
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.